Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas
Authors
Keywords
Gefitinib, Erlotinib, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Nilotinib
Journal
DRUG SAFETY
Volume 39, Issue 11, Pages 1073-1091
Publisher
Springer Nature
Online
2016-08-17
DOI
10.1007/s40264-016-0450-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States. 2000 to 2011
- (2016) John P. Hutchinson et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer
- (2016) Meiko Nishimura et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities
- (2016) Dan Lu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
- (2016) Peng Wu et al. DRUG DISCOVERY TODAY
- Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations
- (2016) Helen E. Jo et al. DRUGS & AGING
- 140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
- (2016) K. Park et al. Journal of Thoracic Oncology
- 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
- (2016) M.-J. Ahn et al. Journal of Thoracic Oncology
- Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer
- (2016) Takashi Hirose et al. LUNG CANCER
- Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib
- (2016) Hiroyuki Kobayashi et al. MEDICAL ONCOLOGY
- Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer
- (2016) Dongsheng Hong et al. MEDICINE
- Diagnostic Yield and Safety of Cryoprobe Transbronchial Lung Biopsy in Diffuse Parenchymal Lung Diseases: Systematic Review and Meta-Analysis
- (2016) S. Dhooria et al. Respiratory Care
- Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
- (2016) Seung-Hoon Beom et al. Cancer Research and Treatment
- Survival of Patients with Stage IV Lung Cancer with Diabetes Treated with Metformin
- (2015) Jenny J. Lin et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline
- (2015) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
- (2015) H. Yoshioka et al. ANNALS OF ONCOLOGY
- Characteristics of and Risk Factors for Interstitial Lung Disease Induced by Chemotherapy for Lung Cancer
- (2015) Takumi Sakurada et al. ANNALS OF PHARMACOTHERAPY
- The Impact of Lung Cancer on Survival of Idiopathic Pulmonary Fibrosis
- (2015) Sara Tomassetti et al. CHEST
- Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis
- (2015) R.-H. Tian et al. Clinical & Translational Oncology
- Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis
- (2015) Andreas Nearchou et al. Clinical Genitourinary Cancer
- Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit
- (2015) Rashmi R. Shah et al. DRUG SAFETY
- The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF: TABLE 1
- (2015) Kevin C. Wilson et al. EUROPEAN RESPIRATORY JOURNAL
- Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
- (2015) Lutz Wollin et al. EUROPEAN RESPIRATORY JOURNAL
- Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis
- (2015) Omar Abdel-Rahman et al. Future Oncology
- Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement–positive non–small cell lung cancer treated with alectinib
- (2015) Yuzo Yamamoto et al. INVESTIGATIONAL NEW DRUGS
- Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review
- (2015) Perrine Créquit et al. Journal of Thoracic Oncology
- Successful treatment with alectinib after crizotinib-induced interstitial lung disease
- (2015) Haruka Chino et al. LUNG CANCER
- Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
- (2015) Masayuki Takeda et al. LUNG CANCER
- Innovation in biologic new molecular entities: 1986–2014
- (2015) Kathleen L. Miller et al. NATURE REVIEWS DRUG DISCOVERY
- Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management
- (2015) Sariah Liu et al. SEMINARS IN ONCOLOGY
- Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis
- (2015) Gaetan Des Guetz et al. Targeted Oncology
- The diagnosis and management of interstitial lung diseases
- (2015) A. Wallis et al. BMJ-British Medical Journal
- The diagnosis and management of interstitial lung diseases
- (2015) A. Wallis et al. BMJ-British Medical Journal
- Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer
- (2014) Akihiko Gemma et al. CANCER SCIENCE
- Metformin Sensitizes EGFR-TKI-Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal
- (2014) L. Li et al. CLINICAL CANCER RESEARCH
- Association Between Baseline Pulmonary Status and Interstitial Lung Disease in Patients With Non–Small-Cell Lung Cancer Treated With Erlotinib—A Cohort Study
- (2014) Takeshi Johkoh et al. Clinical Lung Cancer
- Successful Crizotinib Rechallenge After Crizotinib-Induced Interstitial Lung Disease in Patients With Advanced Non–Small-Cell Lung Cancer
- (2014) Nobuhiro Asai et al. Clinical Lung Cancer
- Incidence and Clinical Features of Drug-induced Lung Injury in Patients with Advanced Colorectal Cancer Receiving Cetuximab: Results of a Prospective Multicenter Registry
- (2014) T. Satoh et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Interstitial lung disease induced by alectinib (CH5424802/RO5424802)
- (2014) S. Ikeda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Successful Crizotinib Rechallenge After Crizotinib-induced Interstitial Lung Disease
- (2014) M. Tachihara et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients†
- (2014) Narikazu Boku et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials
- (2014) Wei-Xiang Qi et al. JOURNAL OF CHEMOTHERAPY
- High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer
- (2014) Ken-ichi Fujita et al. LUNG CANCER
- A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)
- (2014) Xingsheng Hu et al. LUNG CANCER
- Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer
- (2014) Hiroshige Yoshioka et al. LUNG CANCER
- Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres
- (2014) Philipp Ivanyi et al. MEDICAL ONCOLOGY
- Diagnostic yield of transbronchial cryobiopsy in interstitial lung disease: A randomized trial
- (2014) Virginia Pajares et al. RESPIROLOGY
- Advances in kinase targeting: current clinical use and clinical trials
- (2014) Mathias Rask-Andersen et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors
- (2013) Rashmi R. Shah et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
- (2013) Rashmi R. Shah et al. DRUG SAFETY
- Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy
- (2013) Devron R. Shah et al. DRUG SAFETY
- Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)
- (2013) Rashmi R. Shah et al. DRUG SAFETY
- Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors
- (2013) Manuela Schmidinger EJC SUPPLEMENTS
- Nilotinib-induced interstitial lung disease
- (2013) Se-Il Go et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Successful EGFR-TKI Rechallenge of Leptomeningeal Carcinomatosis after Gefitinib-induced Interstitial Lung Disease
- (2013) Shinji Nakamichi et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Interstitial Lung Disease Associated with Gefitinib in Japanese Patients with EGFR-mutated Non-small-cell Lung Cancer: Combined Analysis of Two Phase III Trials (NEJ 002 and WJTOG 3405)
- (2013) Hiroaki Akamatsu et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma
- (2013) Ko-Fan Wang et al. Journal of the Chinese Medical Association
- Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials
- (2013) Liang Shi et al. LUNG CANCER
- Panitumumab-Induced Interstitial Lung Disease in a Case of Metastatic Colorectal Cancer
- (2013) Takeshi Yamada et al. ONKOLOGIE
- Rare Cancer Trial Design: Lessons from FDA Approvals
- (2012) H. Gaddipati et al. CLINICAL CANCER RESEARCH
- Gefitinib-Related Interstitial Lung Disease in Taiwanese Patients With Non–Small-Cell Lung Cancer
- (2012) Shih-Chieh Chang et al. Clinical Lung Cancer
- Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review
- (2012) Yasuko Koma et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data
- (2012) Kim Dao et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
- (2012) M. Takeda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Maximum-Tolerated Dose, Optimum Biologic Dose, or Optimum Clinical Value: Dosing Determination of Cancer Therapies
- (2012) John L. Marshall JOURNAL OF CLINICAL ONCOLOGY
- Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature
- (2012) Yosuke Togashi et al. LUNG CANCER
- Development of imatinibmesylate-induced interstitial lung disease 2 weeks after discontinuation of the treatment: a case report
- (2012) Shota Nakashima et al. MULTIDISCIPLINARY RESPIRATORY MEDICINE
- Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight
- (2011) Ji Hye Min et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review
- (2011) Y.-C. Lai et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease
- (2011) M.-K. Yuan et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib
- (2011) Thomas Delomas et al. LEUKEMIA & LYMPHOMA
- Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature
- (2011) R. ter Heine et al. LUNG CANCER
- Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs
- (2011) R. Dienstmann et al. ONCOLOGIST
- Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study
- (2010) Kaoru Kubota et al. Journal of Thoracic Oncology
- A Case of Radiation Recall Pneumonitis Induced by Erlotinib, Which Can be Related to High Plasma Concentration
- (2010) Yosuke Togashi et al. Journal of Thoracic Oncology
- Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review
- (2010) Li-Chiao Kuo et al. MEDICAL ONCOLOGY
- Interstitial Lung Disease and Gefitinib
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Preexisting Pulmonary Fibrosis Detected on Chest Radiograph and CT on the Development of Gefitinib-Related Interstitial Lung Disease
- (2009) Yoichi Naito et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Examination of the Relationship Between Oncology Drug Labeling Revision Frequency and FDA Product Categorization
- (2009) Robert J. Berlin AMERICAN JOURNAL OF PUBLIC HEALTH
- An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer
- (2009) G. Capri et al. ANNALS OF ONCOLOGY
- Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease
- (2009) Tomoya Fukui et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Gefitinib: Implications for Pulmonary and Hepatic Toxicities
- (2009) Xiaohai Li et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event
- (2009) Shotaro Ide et al. LUNG CANCER
- Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors
- (2008) Bobbak Vahid et al. CHEST
- Recurrent Gefitinib-induced Interstitial Lung Disease
- (2008) Masaru Suzuki et al. INTERNAL MEDICINE
- Overview of Gefitinib in Non-small Cell Lung Cancer: An Asian Perspective
- (2008) H. Jiang JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Fatal Interstitial Lung Disease After Erlotinib for Non-small Cell Lung Cancer
- (2008) Joline S.W. Lind et al. Journal of Thoracic Oncology
- Drug-Induced Pneumonitis Associated with Imatinib Mesylate in a Patient with Idiopathic Pulmonary Fibrosis
- (2006) Hideaki Yamasawa et al. RESPIRATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started